On the stock market since 2013, it operates in the world of money and finance. It has 221 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 17% a year on average.
Sales run at $48.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 10 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $21.2M against $48.0M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, RIVE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RIVE is a high-risk stock — not yet profitable, and its future rides on its product catching on.